Study of the Retinal Vascularization by Laser Doppler Velocimetry Coupled With an Adaptive Optics Camera ( AO-LDV)

Inclusion Criteria: * Willing and able to give written Informed Consent and to comply with the requirements of the study protocol * Person affiliated to social security * Age between 18 and 80 years * Capable of focusing a target without ocular micro stuttering * For healthy subject : absence of ocular and systemic pathology and no medical treatment * For subject with glaucoma : Primitive open-angle glaucoma unilateral or bilateral. Visual field must be considerate as compatible and reliable with campimetric impairment known in glaucoma. * For subject wih retinal veinous occlusion : Retinal central vein occlusion or branch retinal vein occlusion medically confirmed with an eye fundus exam and fluorescein angiography. Non-inclusion Criteria: * Subject mentioned in L1121-5 to L1121-8 article of French Health Code : pregnant women, women capable of child bearing without contraceptive measures, under-age subject, subject under juridic protection or not able to give informed consent, subject deprived of liberty * Any systemic medication with action on intraocular pressure such as sympathomimetic and beta blocker * Hypersensitivity to tropicamide or its derivatives or to any eye drops excipients * Subject who do not want to take part to the study * Subject participating to another clinical trial * Subject who can't come back for follow up visits * Subject with lenses and who can't stop wearing them for the study protocol * Close or narrow anterior chamber angle * For healthy subject : Ametropia \> 3 diopter, subject with non evolutive or evolutive ocular pathology * For subject with glaucoma : Ametropia \> 3 diopter, secondary glaucoma, closed angle glaucoma, isolated intraocular hypertonia, eye surgery within 3 months before the beginning of the study, trabeculoplasty, filtration surgery, associated evolutive or non-evolutive ocular pathology * For subject with retinal veinous occlusion : Ametropia \> 3, associated evolutive or non-evolutive ocular pathology, patient already treated with intravitreal injection with anti-VEGF or dexamethasone implant (no older than 4 months)